Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: A systematic review and meta-analysis of randomized controlled trials

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Chang, Ping Hsun ^a   Chiang, Chien Hsieh ^a   Ho, Wei Che ^a   Wu, Pei Zu ^a   Tsai, Jaw Shiun ^a   Guo, Fei Ran ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Combination therapy; Meta analysis; Nicotine replacement therapy; Smoking cessation; Systematic review; Varenicline

Indexed keywords

NICOTINE GUM; VARENICLINE;

COMBINATION DRUG THERAPY; HUMAN; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION;

DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84937422421     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-2055-0     Document Type: Article

References (36)

1. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer. 2009;9:655-64.
2. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health: The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta GA: Centers for Disease Control and Prevention (US); 2014.
3. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.
4. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008;35:158-76.
5. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588-97.
6. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
7. Smoking cessation services: NICE public health guidance 10 [ http://www.nice.org.uk/guidance/PH10 ]
8. Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009;11:572-6.
9. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014;312:155-61.
10. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC medicine. 2013;11:140.
11. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014;12:172.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
13. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119-29.
14. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123-37.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
17. Tonnesen P, Mikkelsen K. Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. Nicotine Tob Res. 2013;15:419-27.
18. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
19. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
20. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing Jr CB, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32:664-75.
21. Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009;68:669-81.
22. Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol. 2004;72:712-22.
23. Munafo M, Bradburn M, Bowes L, David S. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res. 2004;6:769-76.
24. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10:1245-50.
25. Vangeli E, Stapleton J, Smit ES, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction. 2011;106:2110-21.
26. Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction. 2008;103:557-63.
27. Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology. 2011;214:579-92.
28. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
29. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? Drugs. 2010;70:643-50.
30. Lotfipour S, Mandelkern M, Alvarez-Estrada M, Brody AL. A single administration of low-dose varenicline saturates alpha4beta2∗nicotinic acetylcholine receptors in the human brain. Neuropsychopharmacology. 2012;37:1738-48.
31. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295-303.
32. Centers for Disease Control and Prevention(US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US): How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta GA: Centers for Disease Control and Prevention (US); 2010.
33. Harrison-Woolrych M, Paterson H, Tan M. Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study. Pharmacoepidemiol Drug Saf. 2013;22:1086-92.
34. Kaplan YC, Olgac Dundar N, Kasap B, Karadas B. Pregnancy outcome after varenicline exposure in the first trimester. Case Rep Obstet Gyneco. 2014;2014:263981.
35. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: When Does it Make Sense to Perform a Meta-Analysis? In. Introduction to Meta-Analysis. John Wiley & Sons, Ltd; 2009: 357-364
36. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Fixed-Effect Versus Random-Effects Models. In Introduction to Meta-Analysis. John Wiley & Sons, Ltd; 2009: 77-86